Cargando…

Frontiers in Clinical Drug Research - Hematology.

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Atta-ur-Rahman
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Sharjah : Bentham Science Publishers, 2018.
Colección:Frontiers in Clinical Drug Research - Hematology Ser.
Temas:
Acceso en línea:Texto completo

MARC

LEADER 00000cam a2200000Mu 4500
001 EBOOKCENTRAL_on1038495772
003 OCoLC
005 20240329122006.0
006 m o d
007 cr |n|---|||||
008 180602s2018 xx o 000 0 eng d
040 |a EBLCP  |b eng  |e pn  |c EBLCP  |d OCLCQ  |d VLY  |d OCLCF  |d DST  |d K6U  |d OCLCQ  |d OCLCO 
019 |a 1162111402  |a 1241753229  |a 1289384388  |a 1300669173  |a 1303323555  |a 1303472946 
020 |a 9781681083674 
020 |a 1681083671 
029 1 |a AU@  |b 000070364542 
035 |a (OCoLC)1038495772  |z (OCoLC)1162111402  |z (OCoLC)1241753229  |z (OCoLC)1289384388  |z (OCoLC)1300669173  |z (OCoLC)1303323555  |z (OCoLC)1303472946 
050 4 |a RC636  |b .F766 2018 
082 0 4 |a 616.15  |2 23 
049 |a UAMI 
100 1 |a Atta-ur-Rahman. 
245 1 0 |a Frontiers in Clinical Drug Research - Hematology. 
260 |a Sharjah :  |b Bentham Science Publishers,  |c 2018. 
300 |a 1 online resource (272 pages) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Frontiers in Clinical Drug Research - Hematology Ser. ;  |v v. 3 
588 0 |a Print version record. 
505 0 |a Intro; CONTENTS; PREFACE; List of Contributors; Advances in the Understanding and Treatment of Immune Thrombocytopenia; José Perdomo*; INTRODUCTION; Platelet Biogenesis; Platelet Function; Epidemiology, Aetiology and Disease Progression; Platelet Destruction in ITP; Recent Developments; Impairment of Platelet Production in ITP; Disease Characteristics and Therapies; Need for Novel Therapies; CONCLUDING REMARKS; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Recent Developments in Chronic Myeloid Leukemia Biology and Treatment. 
505 8 |a Massimiliano Bonifacio1,* and Claudio Sorio2,*INTRODUCTION; PART I: BIOLOGY; Signaling Mechanisms Altered in CML; Oncosuppressors Genes in CML: A Role for Cytosolic and Receptor-like PTPs; Oncogenic PTPs; Non-coding RNAs in CML; Other Tumor Promoting Pathways; Identifying Cancer Stem Cell in CML; Targeting LSCs; PART II: CLINICS; OPTIONS OF FRONT-LINE MANAGEMENT OF CML; Imatinib; Nilotinib; Dasatinib; Bosutinib and Ponatinib; THE SEQUENTIAL USE OF TKI IN SECOND OR FURTHER LINES OF TREATMENT; BCR-ABL Mutations; After Imatinib Failure; After Failure of Nilotinib or Dasatinib. 
505 8 |a Indications for HSCTTHE PROGNOSTIC SIGNIFICANCE OF EARLY MOLECULAR RESPONSE; Imatinib; Nilotinib; Dasatinib; Bosutinib; Absolute vs Relative Reduction of BCR-ABL1 Levels; Therapeutic Strategies Based on EMR; DEEP MOLECULAR RESPONSE AND DISCONTINUATION OF TREATMENT; Discontinuation Studies; Predictive Factors of DMR; The Impact of DMR on Survival; PREDICTING RESPONSE TO TKI; Risk Score Systems; Age; Comorbidities; Gender; Cytogenetic at Diagnosis; Transcript Type; Mutations; Predicting Response to 2G TKI After Imatinib Failure; New and Alternative Biomarkers of Response to Treatment. 
505 8 |a CONCLUDING REMARKSABBREVIATIONS; CONSENT FOR PUBLICATION; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Role of Immunomodulatory Drugs in the Treatment of Lymphoid and Myeloid Malignancies; Ota Fuchs*; INTRODUCTION; CRL4CRBN as a Part of Ubiquitin-Proteasome System; Regulation of CRBN-Associated Proteins in Multiple Myeloma by Lenalidomide; Biomarker of Response or Resistance to Lenalidomide and Pomalidomide; Therapy for Multiple Myeloma Patients with Low CRBN Expression; Importance of CRBN for Immunomodulatory Drugs Activity in Lymphoid Malignancies. 
505 8 |a CLINICAL STUDIES IN LYMPHOID MALIGNANCIESRelapsed/ Refractory CLL; B-Cell NHL; Multiple Myeloma; CLINICAL STUDIES IN MYELOID MALIGNANCIES; Myelodysplastic Syndrome; Randomized Phase III Placebo-Controlled Study of Lenalidomide in del(5q) Patients; Further Clinical Studies of Lower Risk MDS Patients with del(5q) Treated with Lenalidomide; Treatment of del(5q) Patients with Relapse during Lenalidomide Exposure; Therapy with Lenalidomide in Combination with Another Drug in MDS; Mechanisms of Action of Lenalidomide. 
500 |a Role of Cereblon in the Efficacy of Lenalidomide in del(5q) MDS and non-del(5q) MDS. 
590 |a ProQuest Ebook Central  |b Ebook Central Academic Complete 
650 0 |a Blood  |x Diseases. 
650 0 |a Hematology. 
650 2 |a Hematologic Diseases 
650 2 |a Hematology 
650 6 |a Sang  |x Maladies. 
650 6 |a Hématologie. 
650 7 |a Blood  |x Diseases  |2 fast 
650 7 |a Hematology  |2 fast 
776 0 8 |i Print version:  |a Atta-ur-Rahman.  |t Frontiers in Clinical Drug Research - Hematology.  |d Sharjah : Bentham Science Publishers, ©2018  |z 9781681083681 
830 0 |a Frontiers in Clinical Drug Research - Hematology Ser. 
856 4 0 |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=5392646  |z Texto completo 
938 |a ProQuest Ebook Central  |b EBLB  |n EBL5392646 
994 |a 92  |b IZTAP